```
=> index patent

FILE 'PAPERCHEM' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         1.05       1.05

INDEX 'CAOLD, CAPLUS, CROPU, DGENE, DPCI, ENCOMPPAT, ENCOMPPAT2, EUROPATFULL,
       IFIPAT, INPADOC, JAPIO, PAPERCHEM2, PATDD, PATDPA, PATOSDE, PATOSEP,
       PATOSWO, PCTFULL, PIRA, RAPRA, SYNTHLINE, TULSA, TULSA2, USPATFULL,
       WPIDS, WPINDEX' ENTERED AT 15:37:35 ON 21 FEB 2001

26 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s protein?

      46089   FILE CAOLD
    1372992   FILE CAPLUS
       5729   FILE CROPU
     529288   FILE DGENE
      21437   FILE DPCI
       1702   FILE ENCOMPPAT
       1702   FILE ENCOMPPAT2
      33321   FILE EUROPATFULL
      33828   FILE IFIPAT
      53922   FILE INPADOC
  10 FILES SEARCHED...
      20137   FILE JAPIO
       8352   FILE PAPERCHEM2
        656   FILE PATDD
      10626   FILE PATDPA
       3189   FILE PATOSDE
      13600   FILE PATOSEP
      16564   FILE PATOSWO
      69480   FILE PCTFULL
        734   FILE PIRA
       2379   FILE RAPRA
         40   FILE SYNTHLINE
        534   FILE TULSA
        444   FILE TULSA2
     108996   FILE USPATFULL
      83543   FILE WPIDS
      83543   FILE WPINDEX

  26 FILES HAVE ONE OR MORE ANSWERS,   26 FILES SEARCHED IN STNINDEX

L1   QUE PROTEIN?

=> file hit

COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         2.04       3.09

FILE 'CAPLUS' ENTERED AT 15:39:58 ON 21 FEB 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
```

COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 15:39:58 ON 21 FEB 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'USPATFULL' ENTERED AT 15:39:58 ON 21 FEB 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 15:39:58 ON 21 FEB 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'PCTFULL' ENTERED AT 15:39:58 ON 21 FEB 2001
COPYRIGHT (C) 2001 MicroPatent

FILE 'INPADOC' ENTERED AT 15:39:58 ON 21 FEB 2001
COPYRIGHT (C) 2001 European Patent Office, Vienna (EPO)

FILE 'CAOLD' ENTERED AT 15:39:58 ON 21 FEB 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'IFIPAT' ENTERED AT 15:39:58 ON 21 FEB 2001
COPYRIGHT (C) 2001 IFI CLAIMS(R) Patent Services (IFI)

FILE 'EUROPATFULL' ENTERED AT 15:39:58 ON 21 FEB 2001
COPYRIGHT (c) 2001 WILA Verlag Muenchen (WILA)

FILE 'DPCI' ENTERED AT 15:39:58 ON 21 FEB 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'JAPIO' ENTERED AT 15:39:58 ON 21 FEB 2001
COPYRIGHT (C) 2001 Japanese Patent Office (JPO)

FILE 'PATOSWO' ENTERED AT 15:39:58 ON 21 FEB 2001
COPYRIGHT (c) 2001 WILA Verlag Muenchen (WILA)

FILE 'PATOSEP' ENTERED AT 15:39:58 ON 21 FEB 2001
COPYRIGHT (c) 2001 WILA Verlag Muenchen (WILA)

FILE 'PATDPA' ENTERED AT 15:39:58 ON 21 FEB 2001
COPYRIGHT (c) 2001 Deutsches Patent- und Markenamt / FIZ Karlsruhe (DPMA/FIZ KA)

FILE 'PAPERCHEM2' ENTERED AT 15:39:58 ON 21 FEB 2001
COPYRIGHT (C) 2001 Institute of Paper Science and Technology (IPST)

FILE 'CROPU' ENTERED AT 15:39:58 ON 21 FEB 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'PATOSDE' ENTERED AT 15:39:58 ON 21 FEB 2001
COPYRIGHT (c) 2001 WILA Verlag Muenchen (WILA)

FILE 'RAPRA' ENTERED AT 15:39:58 ON 21 FEB 2001
COPYRIGHT (C) 2001 RAPRA Technology Ltd.

FILE 'ENCOMPPAT' ENTERED AT 15:39:58 ON 21 FEB 2001
Abstracts copyright (C) Derwent Information Ltd.
Remainder of the file copyright (C) 2001 Elsevier Engineering Information, Inc. (DERWENT/ELSEVIER)

FILE 'ENCOMPPAT2' ENTERED AT 15:39:58 ON 21 FEB 2001
Abstracts copyright (C) Derwent Information Ltd.
Remainder of the file copyright (C) 2001 Elsevier Engineering

```
Information, Inc. (DERWENT/ELSEVIER)

FILE 'PIRA' ENTERED AT 15:39:58 ON 21 FEB 2001
COPYRIGHT (C) 2001 Pira International

FILE 'PATDD' ENTERED AT 15:39:58 ON 21 FEB 2001
COPYRIGHT 2001 (C) Deutsches Patent- und Markenamt (DPMA)

FILE 'TULSA' ENTERED AT 15:39:58 ON 21 FEB 2001
COPYRIGHT (C) 2001 The University of Tulsa (UTULSA)

FILE 'TULSA2' ENTERED AT 15:39:58 ON 21 FEB 2001
COPYRIGHT (C) 2001 The University of Tulsa (UTULSA)

FILE 'SYNTHLINE' ENTERED AT 15:39:58 ON 21 FEB 2001
COPYRIGHT (C) 2001 Prous Science

=> s l1

   5 FILES SEARCHED...
  11 FILES SEARCHED...
L2     2439284 L1

=>  s l2 and regulat? and recept? and nuclear? and librar?

   5 FILES SEARCHED...
  19 FILES SEARCHED...
L3        8774 L2 AND REGULAT? AND RECEPT? AND NUCLEAR? AND LIBRAR?

=> s l3 and method? and nuclear? receptor?

   5 FILES SEARCHED...
   9 FILES SEARCHED...
L4         469 L3 AND METHOD? AND NUCLEAR? RECEPTOR?

=> dup rem l4

DUPLICATE IS NOT AVAILABLE IN 'DGENE, CAOLD, DPCI, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING IS APPROXIMATELY  49% COMPLETE FOR L4
PROCESSING IS APPROXIMATELY  72% COMPLETE FOR L4
PROCESSING COMPLETED FOR L4
L5          462 DUP REM L4 (7 DUPLICATES REMOVED)

=> s l5 and motif?

   3 FILES SEARCHED...
   5 FILES SEARCHED...
  12 FILES SEARCHED...
L6         268 L5 AND MOTIF?

=> d his


     (FILE 'HOME' ENTERED AT 15:34:28 ON 21 FEB 2001)

     INDEX 'CAOLD, CAPLUS, CROPU, DGENE, DPCI, ENCOMPPAT, ENCOMPPAT2,
     EUROPATFULL, IFIPAT, INPADOC, JAPIO, PAPERCHEM2, PATDD, PATDPA, PATOSDE,
     PATOSEP, PATOSWO, PCTFULL, PIRA, RAPRA, SYNTHLINE, TULSA, TULSA2,
     USPATFULL, WPIDS, WPINDEX' ENTERED AT 15:37:35 ON 21 FEB 2001
               SEA PROTEIN?
              ---------
          46089   FILE CAOLD
        1372992   FILE CAPLUS
           5729   FILE CROPU
         529288   FILE DGENE
```

```
             21437   FILE DPCI
              1702   FILE ENCOMPPAT
              1702   FILE ENCOMPPAT2
             33321   FILE EUROPATFULL
             33828   FILE IFIPAT
             53922   FILE INPADOC
             20137   FILE JAPIO
              8352   FILE PAPERCHEM2
               656   FILE PATDD
             10626   FILE PATDPA
              3189   FILE PATOSDE
             13600   FILE PATOSEP
             16564   FILE PATOSWO
             69480   FILE PCTFULL
               734   FILE PIRA
              2379   FILE RAPRA
                40   FILE SYNTHLINE
               534   FILE TULSA
               444   FILE TULSA2
            108996   FILE USPATFULL
             83543   FILE WPIDS
             83543   FILE WPINDEX
L1               QUE PROTEIN?
                 ---------

     FILE 'CAPLUS, DGENE, USPATFULL, WPIDS, PCTFULL, INPADOC, CAOLD, IFIPAT,
     EUROPATFULL, DPCI, JAPIO, PATOSWO, PATOSEP, PATDPA, PAPERCHEM2, CROPU,
     PATOSDE, RAPRA, ENCOMPPAT, ENCOMPPAT2, PIRA, PATDD, TULSA, TULSA2,
     SYNTHLINE' ENTERED AT 15:39:58 ON 21 FEB 2001
L2        2439284 S L1
L3           8774 S L2 AND REGULAT? AND RECEPT? AND NUCLEAR? AND LIBRAR?
L4            469 S L3 AND METHOD? AND NUCLEAR? RECEPTOR?
L5            462 DUP REM L4 (7 DUPLICATES REMOVED)
L6            268 S L5 AND MOTIF?

=> s l6 and regulat? protein?

   2 FILES SEARCHED...
   9 FILES SEARCHED...
L7            117 L6 AND REGULAT? PROTEIN?

=> d ti 1-10


L7   ANSWER 1 OF 117  USPATFULL
TI     Mutations in the diabetes susceptibility genes hepatocyte
     **nuclear** factor (HNF) 1 alpha (.alpha.), HNF1.beta. and
       HNF4.alpha.

L7   ANSWER 2 OF 117  USPATFULL
TI     Genomic DNA fragments containing **regulatory** and coding
       sequences for the .beta.2-subunit of the neuronal nicotinic
       acetylcholine **receptor** and transgenic animals made using these
       fragments or mutated fragments

L7   ANSWER 3 OF 117  USPATFULL
TI     **Method** for treating allergic lung disease

L7   ANSWER 4 OF 117  USPATFULL
TI     **Methods** and compositions relating to no-mediated cytotoxicity

L7   ANSWER 5 OF 117  USPATFULL
TI     Telomerase catalytic subunit

L7   ANSWER 6 OF 117  USPATFULL
TI     Recombinant yeast cells for identifying **receptor** effectors
```

L7 ANSWER 7 OF 117 USPATFULL
TI **Method** of controlling the fertility of a plant

L7 ANSWER 8 OF 117 USPATFULL
TI Therapeutic compositions and **methods** and diagnostic assays for type II diabetes involving HNF-1

L7 ANSWER 9 OF 117 USPATFULL
TI Human thyroid **protein** zsig45

L7 ANSWER 10 OF 117 USPATFULL
TI Insulin-like growth factor agonist molecules

=> d ti 11-20

L7 ANSWER 11 OF 117 USPATFULL
TI DNA vaccines for eliciting a mucosal immune response

L7 ANSWER 12 OF 117 USPATFULL
TI Chimeric **proteins** comprising liver enriched transcription factors and nucleic acids encoding the same

L7 ANSWER 13 OF 117 USPATFULL
TI **Method** for identifying substances that affect the interaction of a presenilin-1-interacting **protein** with a mammalian presenilin-1 **protein**

L7 ANSWER 14 OF 117 USPATFULL
TI Programmable genotoxic agents and uses therefor

L7 ANSWER 15 OF 117 USPATFULL
TI Control of gene expression in plants by **receptor** mediated transactivation in the presence of a chemical ligand

L7 ANSWER 16 OF 117 USPATFULL
TI Programmable genotoxic agents and uses therefor

L7 ANSWER 17 OF 117 USPATFULL
TI **Method** for treating allergic lung disease

L7 ANSWER 18 OF 117 USPATFULL
TI Liver enriched transcription factor

L7 ANSWER 19 OF 117 USPATFULL
TI **Methods** and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides

L7 ANSWER 20 OF 117 USPATFULL
TI **Methods** for identifying compounds useful in treating type II diabetes

=> s l7 and nucleic? acid?

2 FILES SEARCHED...
3 FILES SEARCHED...
5 FILES SEARCHED...
9 FILES SEARCHED...
L8 112 L7 AND NUCLEIC? ACID?

=> s l8 and py<04191998

<------User Break------>

<-----User Break----->

SEARCH ENDED BY USERu
=>
=> s l8 and prolin? and rich?

11 FILES SEARCHED...
21 FILES SEARCHED...
L9 62 L8 AND PROLIN? AND RICH?

=> dup rem l9

DUPLICATE IS NOT AVAILABLE IN 'DGENE, CAOLD, DPCI, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L9
L10 62 DUP REM L9 (0 DUPLICATES REMOVED)

=> d ti 1-20

L10 ANSWER 1 OF 62 USPATFULL
TI Mutations in the diabetes susceptibility genes hepatocyte **nuclear** factor (HNF) 1 alpha (.alpha.), HNF1.beta. and HNF4.alpha.

L10 ANSWER 2 OF 62 USPATFULL
TI **Methods** and compositions relating to no-mediated cytotoxicity

L10 ANSWER 3 OF 62 PCTFULL COPYRIGHT 2001 MicroPatent
TIEN NOVEL HUMAN GENES AND GENE EXPRESSION PRODUCTS
TIFR NOUVEAUX GENES HUMAINS ET PRODUITS D#apos#EXPRESSION GENIQUE

L10 ANSWER 4 OF 62 USPATFULL
TI Telomerase catalytic subunit

L10 ANSWER 5 OF 62 USPATFULL
TI Recombinant yeast cells for identifying **receptor** effectors

L10 ANSWER 6 OF 62 USPATFULL
TI Therapeutic compositions and **methods** and diagnostic assays for type II diabetes involving HNF-1

L10 ANSWER 7 OF 62 USPATFULL
TI Insulin-like growth factor agonist molecules

L10 ANSWER 8 OF 62 USPATFULL
TI Chimeric **proteins** comprising liver enriched transcription factors and **nucleic acids** encoding the same

L10 ANSWER 9 OF 62 PCTFULL COPYRIGHT 2001 MicroPatent
TIEN MOLECULES FOR DIAGNOSTICS AND THERAPEUTICS
TIFR MOLECULES UTILISEES A DES FINS DIAGNOSTIQUES ET THERAPEUTIQUES

L10 ANSWER 10 OF 62 PCTFULL COPYRIGHT 2001 MicroPatent
TIEN BRIDGE-1, A TRANSCRIPTION FACTOR
TIFR #le#BRIDGE-1#ge#, UN FACTEUR DE TRANSCRIPTION

L10 ANSWER 11 OF 62 PCTFULL COPYRIGHT 2001 MicroPatent
TIEN NUCLEIC ACIDS INCLUDING OPEN READING FRAMES ENCODING POLYPEPTIDES; "ORFX"
TIFR ACIDES NUCLEIQUES COMPRENANT DES PHASES DE LECTURE OUVERTE CODANT DES POLYPEPTIDES; #le#ORFX#ge#

L10 ANSWER 12 OF 62 PCTFULL COPYRIGHT 2001 MicroPatent
TIEN HUMAN PANCREAS AND PANCREATIC CANCER ASSOCIATED GENE SEQUENCES AND POLYPEPTIDES

TIFR SEQUENCES DE GENES ET POLYPEPTIDES ASSOCIEES AU CANCER DU PANCREAS CHEZ L'HOMME

L10 ANSWER 13 OF 62 PCTFULL COPYRIGHT 2001 MicroPatent
TIEN HUMAN LUNG CANCER ASSOCIATED GENE SEQUENCES AND POLYPEPTIDES
TIFR SEQUENCES ET POLYPEPTIDES GENIQUES ASSOCIES AU CANCER DU POUMON CHEZ L'HOMME

L10 ANSWER 14 OF 62 PCTFULL COPYRIGHT 2001 MicroPatent
TIEN **METHODS** AND COMPOSITIONS FOR **REGULATING** MEMORY CONSOLIDATION
TIFR **METHODES** ET COMPOSITIONS PERMETTANT DE REGULER LA CONSOLIDATION DE LA MEMOIRE

L10 ANSWER 15 OF 62 PCTFULL COPYRIGHT 2001 MicroPatent
TIEN SCARECROW GENE, PROMOTER AND USES THEREOF
TIFR GENE SCARECROW, SON PROMOTEUR ET SES UTILISATIONS

L10 ANSWER 16 OF 62 PCTFULL COPYRIGHT 2001 MicroPatent
TIEN GENERATION OF DIAGNOSTIC TOOLS TO ASSAY THE HUMAN LHX3/P-LIM/LIM-3 FACTOR
TIFR GENERATION D'OUTILS DE DIAGNOSTIC POUR DOSER LE FACTEUR LHX3/P-LIM/LIM-3 HUMAIN

L10 ANSWER 17 OF 62 PCTFULL COPYRIGHT 2001 MicroPatent
TIEN GENE SEQUENCE VARIATIONS WITH UTILITY IN DETERMINING THE TREATMENT OF DISEASE
TIFR VARIATIONS DE SEQUENCES GENIQUES PRESENTANT UNE UTILITE POUR LA SELECTION DU TRAITEMENT D'UNE MALADIE

L10 ANSWER 18 OF 62 PCTFULL COPYRIGHT 2001 MicroPatent
TIEN FXR **RECEPTOR**-MEDIATED MODULATION OF CHOLESTEROL METABOLISM
TIFR MODULATION DU METABOLISME DU CHOLESTEROL INDUITE PAR LE **RECEPTEUR** FXR

L10 ANSWER 19 OF 62 PCTFULL COPYRIGHT 2001 MicroPatent
TIEN **METHOD** FOR THE DETECTION OF GENE TRANSCRIPTS IN BLOOD AND USES THEREOF
TIFR TECHNIQUE DE DETECTION DE TRANSCRITS GENIQUES DANS LE SANG ET LEUR UTILISATION

L10 ANSWER 20 OF 62 PCTFULL COPYRIGHT 2001 MicroPatent
TIEN HUMAN GENES AND GENE EXPRESSION PRODUCTS
TIFR GENES HUMAINS ET PRODUITS D'EXPRESSION GENIQUE

=> s l10 and py<1998
<------User Break------>
<------User Break------>
u
SEARCH ENDED BY USER

=> s l10 and py<=1998

3 FILES SEARCHED...
4 FILES SEARCHED...
6 FILES SEARCHED...
10 FILES SEARCHED...
12 FILES SEARCHED...
14 FILES SEARCHED...
17 FILES SEARCHED...
22 FILES SEARCHED...
L11 26 L10 AND PY<=1998

=> d ibib ab 1-26

L11 ANSWER 1 OF 26 USPATFULL
ACCESSION NUMBER: 1998:157103 USPATFULL
TITLE: Liver enriched transcription factor
INVENTOR(S): Sladek, Frances M., Riverside, CA, United States
Zhong, Weimin, New York, NY, United States
Darnell, Jr., James E., Larchmont, NY, United States
PATENT ASSIGNEE(S): The Rockefeller University, New York, NY, United States
(U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 5849485	19981215	<--
APPLICATION INFO.:	US 1996-661330	19960614 (8)	

RELATED APPLN. INFO.: Division of Ser. No. US 1993-78222, filed on 28 Oct 1993, now patented, Pat. No. US 5604115, issued on 18 Feb 1997 which is a continuation of Ser. No. US 1990-631720, filed on 21 Dec 1990, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Lau, Kawai
LEGAL REPRESENTATIVE: Klauber & Jackson
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 2384
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB HNF-4 (hepatocyte **nuclear** factor 4) is a **protein** enriched in liver extracts that binds to sites required for the transcription of the transthyretin (TTR) and apolipoprotein CIII (apoCIII) genes (Costa et al., 1989; Costa et al., 1990; Leff et al., 1989). We have purified HNF-4 **protein** (54 kD) and isolated a cDNA clone encoding the **protein**. HNF-4 is a member of the steroid hormone **receptor** superfamily with an unusual amino acid in the conserved "knuckle" of the first zinc finger (DGCKG). This and the fact that HNF-4 does not bind significantly to estrogen, thyroid hormone or glucocorticoid response elements indicate that HNF-4 may represent a new subfamily. HNF-4 binds to its recognition site as a dimer and activates transcription in a sequence-specific fashion in nonhepatic (HeLa) cells. HNF-4 mRNA is present in kidney and intestine as well as liver but is absent in other tissues. DNA binding data suggest that HNF-4 could be identical to liver factor A1 (LF-A1), a factor previously shown to **regulate** the transcription of the .alpha.-1 antitrypsin, apolipoprotein A1 and pyruvate kinase genes.

L11 ANSWER 2 OF 26 USPATFULL
ACCESSION NUMBER: 1998:98755 USPATFULL
TITLE: **Methods** for identifying compounds useful in treating type II diabetes
INVENTOR(S): Glucksmann, M. Alexandra, Somerville, MA, United States
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 5795726	19980818	<--
APPLICATION INFO.:	US 1997-782047	19970110 (8)	

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1996-760246, filed on 4 Dec 1996 which is a continuation-in-part of Ser. No. US 1996-749431, filed on 15 Nov 1996 which is a continuation-in-part of Ser. No. US 1996-748229, filed on 12 Nov 1996, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Saunders, David
ASSISTANT EXAMINER: VanderVegt, F. Pierre
LEGAL REPRESENTATIVE: Arnold, Esq., Beth E.Foley, Hoag & Eliot LLP
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 4150
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB **Methods** for identifying compounds, which modulate the bioactivity of human hepatic **nuclear** factor-1 (HNF-1), and which are therefore useful in treating type II diabetes are disclosed.

L11 ANSWER 3 OF 26 USPATFULL
ACCESSION NUMBER: 97:51869 USPATFULL
TITLE: Isolated **nucleic acid** encoding a ubiquitous **nuclear receptor**
INVENTOR(S): Liao, Shutsung, Chicago, IL, United States
Song, Ching, Durham, NC, United States
PATENT ASSIGNEE(S): Arch Development Corporation, Chicago, IL, United States (U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 5639616	19970617	<--
APPLICATION INFO.:	US 1994-342411	19941118 (8)	

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-152003, filed on 10 Nov 1993, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Walsh, Stephen G.
ASSISTANT EXAMINER: Ulm, John D.
LEGAL REPRESENTATIVE: Arnold White & Durkee
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing Figure(s); 18 Drawing Page(s)
LINE COUNT: 4472
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates generally to compositions of and **methods** for obtaining ubiquitous, **nuclear receptor** (UR) polypeptides. The invention also relates to polynucleotides encoding UR polypeptides, recombinant host cells and vectors containing UR-encoding polynucleotide sequences, and recombinant UR polypeptides. By way of example, the invention discloses the cloning and functional expression of at least two different UR polypeptides. The invention also includes **methods** for using the isolated, recombinant **receptor** polypeptides in assays designed to select substances which interact with UR polypeptides for use in diagnostic, drug design and therapeutic applications.

L11 ANSWER 4 OF 26 USPATFULL
ACCESSION NUMBER: 97:16172 USPATFULL
TITLE: Mineralocorticoid **receptor** compositions and **methods**
INVENTOR(S): Evans, Ronald M., San Diego, CA, United States
Weinberger, Cary A., Silver Spring, MD, United States
Giguere, Vincent, San Diego, CA, United States
Arriza, Jeffrey, Carlsbad, CA, United States
Thompson, Catherine C., La Jolla, CA, United States
Ong, Estelita S., San Diego, CA, United States
PATENT ASSIGNEE(S): The Salk Institute For Biological Studies, La Jolla, CA, United States (U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 5606021	19970225	<--

APPLICATION INFO.: US 1993-170085 19931217 (8)
RELATED APPLN. INFO.: Division of Ser. No. US 1991-667602, filed on 7 Mar 1991, now patented, Pat. No. US 5312732 which is a division of Ser. No. US 1987-108471, filed on 20 Oct 1987, now patented, Pat. No. US 5071773 which is a continuation-in-part of Ser. No. US 1986-922585, filed on 24 Oct 1986, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Ulm, John
LEGAL REPRESENTATIVE: Pretty, Schoreder, Brueggemann & Clark; Reiter, Stephen E.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 95 Drawing Figure(s); 79 Drawing Page(s)
LINE COUNT: 4454
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides recombinant **proteins** having the hormone-binding and/or transcription-activating characteristics of a mineralocorticoid **receptor**. The invention also provides **proteins** expressed from recombinant DNA encoding a naturally occurring **receptor** having the hormone-binding and/or transcription-activating characteristics of a mineralocorticoid **receptor**.

L11 ANSWER 5 OF 26 USPATFULL
ACCESSION NUMBER: 97:14592 USPATFULL
TITLE: Liver enriched transcription factor
INVENTOR(S): Sladek, Frances M., Riverside, CA, United States
Zhong, Weimin, New York, NY, United States
Darnell, Jr., James E., Larchmont, NY, United States
PATENT ASSIGNEE(S): The Rockefeller University, New York, NY, United States
(U.S. corporation)

	NUMBER	DATE		
PATENT INFORMATION:	US 5604115	19970218		<--
	WO 9211365	19920907		<--
APPLICATION INFO.:	US 1993-78222	19931028	(8)	
	WO 1991-US9733	19911223		
		19931028	PCT 371 date	
		19931028	PCT 102(e) date	

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Lau, Kawai
LEGAL REPRESENTATIVE: Klauber & Jackson
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 2424
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB HNF-4 (hepatocyte **nuclear** factor 4) is a **protein** enriched in liver extracts that binds to sites required for the transcription of the transthyretin (TTR) and apolipoprotein CIII (apoCIII) genes (Costa et al., 1989; Costa et al., 1990; Leff et al., 1989). We have purified HNF-4 **protein** (54 kD) and isolated a cDNA clone encoding the **protein**. HNF-4 is a member of the steroid hormone **receptor** superfamily with an unusual amino acid in the conserved "knuckle" of the first zinc finger (DGCKG). This and the fact that HNF-4 does not bind significantly to estrogen, thyroid hormone or glucocorticoid response elements indicate that HNF-4 may represent a new subfamily. HNF-4 binds to its recognition site as a dimer and activates transcription in a sequence-specific fashion in nonhepatic (HeLa) cells. HNF-4 mRNA is present in kidney and intestine

as well as liver but is absent in other tissues. DNA binding data suggest that HNF-4 could be identical to liver factor A1 (LF-A1), a factor previously shown to **regulate** the transcription of the .alpha.-1 antitrypsin, apolipoprotein A1 and pyruvate kinase genes.

L11 ANSWER 6 OF 26 USPATFULL

ACCESSION NUMBER:	97:7813 USPATFULL
TITLE:	DNA encoding thyroid hormone **receptor** compositions and **methods**
INVENTOR(S):	Evans, Ronald M., San Diego, CA, United States Weinberger, Cary A., Silver Springs, MD, United States Hollenberg, Stanley M., San Diego, CA, United States Giguere, Vincent, San Diego, CA, United States Arriza, Jeffrey, Carlsbad, CA, United States Thompson, Catherine C., La Jolla, CA, United States Ong, Estelita S., San Diego, CA, United States
PATENT ASSIGNEE(S):	The Salk Institute for Biological Studies, La Jolla, CA, United States (U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 5597705	19970128	<--
APPLICATION INFO.:	US 1993-165708	19931210 (8)	

RELATED APPLN. INFO.: Division of Ser. No. US 1991-667602, filed on 7 Mar 1991, now patented, Pat. No. US 5312732 which is a division of Ser. No. US 1987-108471, filed on 20 Oct 1987, now patented, Pat. No. US 5071773 which is a continuation-in-part of Ser. No. US 1986-922585, filed on 24 Oct 1986, now abandoned

DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	Ulm, John
LEGAL REPRESENTATIVE:	Pretty Schroeder Brueggemann & Clark; Reiter, Stephen E.; Raymer, Gregory P.
NUMBER OF CLAIMS:	15
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	98 Drawing Figure(s); 80 Drawing Page(s)
LINE COUNT:	4516

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a recombinant expression system for production of functional thyroid hormone **receptor protein**(s). The invention also provides a **method** to produce thyroid hormone **receptor protein**(s) by culturing the cells of the invention recombinant expression system. Also provided are thyroid hormone **receptor protein**(s) produced by the invention **method**. In addition, the present invention provides recombinant DNAs comprised of sequences which encode **proteins** having the hormone-binding and/or transcription-activating characteristics of a thyroid hormone **receptor**. The invention also provides various plasmids containing **receptor** sequences which exemplify the DNAs of the invention. The invention further provides complementary mRNAs, cells transformed with invention DNAs, and **nucleic acid** probes derived from invention DNAs.

L11 ANSWER 7 OF 26 USPATFULL

ACCESSION NUMBER:	96:60604 USPATFULL
TITLE:	Controlled expression of recombinant **proteins**
INVENTOR(S):	Evans, Roland M., La Jolla, CA, United States Weinberger, Cary A., Silver Springs, MD, United States Hollenberg, Stanley M., Seattle, WA, United States Giguere, Vincent, Etobicoke, Canada Arriza, Jeffrey, Carlsbad, CA, United States Thompson, Catherine C., La Jolla, CA, United States Ong, Estelita S., San Diego, CA, United States
PATENT ASSIGNEE(S):	The Salk Institute for Biological Studies, La Jolla,

CA, United States (U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 5534418	19960709	<--
APPLICATION INFO.:	US 1993-166177	19931210 (8)	

RELATED APPLN. INFO.: Division of Ser. No. US 1991-667602, filed on 7 Mar 1991, now patented, Pat. No. US 5312732 which is a division of Ser. No. US 1987-108471, filed on 20 Oct 1987, now patented, Pat. No. US 5071773 which is a continuation-in-part of Ser. No. US 1986-922585, filed on 24 Oct 1986, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Ulm, John
LEGAL REPRESENTATIVE: Reiter, Stephen E.Pretty, Schroeder, Brueggemann & Clark
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 77 Drawing Figure(s); 79 Drawing Page(s)
LINE COUNT: 4990
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides **methods** for the controlled production of recombinant **proteins** in cells. Cells employed in the invention **method** contain a gene encoding the desired recombinant **protein**, with transcription of the gene maintained under the control of a transcriptional control element which is activated by a ligand/**receptor** complex. The ligand/**receptor** complex is formed when a ligand (which is a hormone or/and analog thereof) is complexed with a **receptor** (which is a hormone **receptor** or functional analog thereof which has the transcription activating properties of the **receptor**). **Receptor** is produced by the expression of non-endogenous DNA which is also present in the cells used for production of recombinant **protein**.

L11 ANSWER 8 OF 26 USPATFULL
ACCESSION NUMBER: 95:103380 USPATFULL
TITLE: Steroid/thyroid hormone **receptor**-related gene, which is inappropriately expressed in human heptocellular carcinoma, and which is a retinoic acid **receptor**

INVENTOR(S): Blaudin De The, Hughes, Faculty of Medicine, 75003 Paris, France
Marchio, Agnes, Faculty of Medicine, 75011 Paris, France
Tiollais, Pierre, Faculty of Medicine, 75013 Paris, France
DeJean, Anne, Faculty of Medicine, 75014 Paris, France
Brand, Nigel, Faculty of Medicine, 67085 Strasbourg, France
Petkovich, Martin, Faculty of Medicine, 67085 Strasbourg, France
Krust, Andree, Faculty of Medicine, 67085 Strasbourg, France
Chambon, Pierre, Faculty of Medicine, 67085 Strasbourg, France

	NUMBER	DATE	
PATENT INFORMATION:	US 5468617	19951121	<--
APPLICATION INFO.:	US 1994-190555	19940202 (8)	

RELATED APPLN. INFO.: Division of Ser. No. US 1993-95706, filed on 22 Jul 1993, now patented, Pat. No. US 5358848 which is a division of Ser. No. US 1992-989902, filed on 11 Dec 1992, now patented, Pat. No. US 5317090 which is a

continuation of Ser. No. US 1992-860577, filed on 30 Mar 1992, now abandoned which is a continuation of Ser.

No. US 1991-751612, filed on 21 Aug 1991, now abandoned

which is a continuation of Ser. No. US 1989-330405, filed on 30 Mar 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-278136, filed on 30 Nov 1988, now abandoned which is a continuation-in-part of Ser. No. US 1988-209009, filed on 20 Jun 1988, now patented, Pat. No. US 5149781 which

is a continuation-in-part of Ser. No. US 1987-134130, filed on 17 Dec 1987, now patented, Pat. No. US 5223606

which is a continuation-in-part of Ser. No. US 1987-133687, filed on 16 Dec 1987, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Nucker, Christine M.
ASSISTANT EXAMINER: Scheiner, Laurie
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 29 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 2011
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A previously isolated hepatitis B virus (HBV) integration in a 147 bp cellular DNA fragment linked to hepatocellular carcinoma (HCC) was used as a probe to clone the corresponding complementary DNA from a human liver cDNA **library**. Nucleotide sequence analysis revealed that the overall structure of the cellular gene, which has been named hap, is similar to that of the DNA-binding hormone **receptors**. Six out of seven hepatoma and hepatoma-derived cell-lines express a 2.5 kb hap mRNA species which is undetectable in normal adult and fetal livers, but present in all non-hepatic tissues analyzed. Low stringency hybridization experiments revealed the existence of hap related genes in the human genome. The cloned DNA sequence is useful in the preparation of pure hap **protein** and as a probe in the detection and isolation of complementary DNA and RNA sequences. The hap **protein** is a retinoic acid (RA) **receptor** identified as RAR-.beta.. The RAR-.beta. gene is transcriptionally up-**regulated** by retinoic acid (RA) and its promoter region may contain a RARE (retinoic acid responsive element).

L11 ANSWER 9 OF 26 USPATFULL
ACCESSION NUMBER: 94:112894 USPATFULL
TITLE: Steroid/thyroid hormone **receptor**-related gene, which is inappropriately expressed in human heptocellular carcinoma, and which is a retinoic acid **receptor**
INVENTOR(S): De The, Hughes B., Paris, France
Marchio, Agnes, Paris, France
Tiollais, Pierre, Paris, France
DeJean, Anne, Paris, France
Brand, Nigel, Strasbourg, France
Petkovich, Martin, Strasbourg, France
Krust, Andree, Strasbourg, France
Chambon, Pierre, Strasbourg, France
PATENT ASSIGNEE(S): Institut Pasteur, Paris Cedex, France (non-U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 5376530	19941227	<--

APPLICATION INFO.: US 1993-95706 19930722 (8)
RELATED APPLN. INFO.: Division of Ser. No. US 1992-989902, filed on 11 Dec 1992 which is a continuation of Ser. No. US 1992-860577, filed on 30 Mar 1992, now abandoned which is a continuation of Ser. No. US 1991-751612, filed on 21 Aug 1991, now abandoned which is a continuation of Ser. No. US 1989-330405, filed on 30 Mar 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-278136, filed on 30 Nov 1988, now abandoned which is a continuation-in-part of Ser. No. US 1988-209009, filed on 20 Jun 1988, now patented, Pat. No. US 5149781 which is a continuation-in-part of Ser. No. US 1987-134130, filed on 17 Dec 1987, now patented,

Pat. No. US 5223606 which is a continuation-in-part of Ser. No. US 1987-133687, filed on 16 Dec 1987, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Nucker, Christine M.
ASSISTANT EXAMINER: Scheiner, Laurie
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow, Garrett & Dunner
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 29 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 1943
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A previously isolated hepatitis B virus (HBV) integration in a 147 bp cellular DNA fragment linked to hepatocellular carcinoma (HCC) was used as a probe to clone the corresponding complementary DNA from a human liver cDNA **library**. Nucleotide sequence analysis revealed that the overall structure of the cellular gene, which has been named hap, is similar to that of the DNA-binding hormone **receptors**. Six out of seven hepatoma and hepatoma-derived cell-lines express a 2.5 kb hap mRNA species which is undetectable in normal adult and fetal livers, but present in all non-hepatic tissues analyzed. Low stringency hybridization experiments revealed the existence of hap related genes in the human genome. The cloned DNA sequence is useful in the preparation of pure hap **protein** and as a probe in the detection and isolation of complementary DNA and RNA sequences. The hap **protein** is a retinoic acid (RA) **receptor** identified as RAR-.beta.. The RAR-.beta. gene is transcriptionally up-**regulated** by retinoic acid (RA) and its promoter region may contain a RARE (retinoic acid responsive element).

L11 ANSWER 10 OF 26 USPATFULL
ACCESSION NUMBER: 94:47046 USPATFULL
TITLE: Steroid/thyroid hormone **receptor**-related gene, which is inappropriately expressed in human hepatocellular carcinoma, and which is a retinoic acid **receptor**
INVENTOR(S): Blaudin De The, Hughes, Paris, France
Marchio, Agnes, Paris, France
Tiollais, Pierre, Paris, France
Dejean, Anne, Paris, France
Brand, Nigel, Strasbourg, France
Petkovich, Martin, Strasbourg, France
Krust, Andree, Strasbourg, France
Chambon, Pierre, Strasbourg, France
PATENT ASSIGNEE(S): Institut Pasteur, Paris, France (non-U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 5317090	19940531	<--

APPLICATION INFO.: US 1992-989902 19921211 (7)
RELATED APPLN. INFO.: Continuation of Ser. No. US 1992-860577, filed on 30 Mar 1992, now abandoned which is a continuation of Ser.
No. US 1991-751612, filed on 21 Aug 1991, now abandoned
which is a continuation of Ser. No. US 1989-330405, filed on 30 Mar 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-278136, filed on 30 Nov 1988, now abandoned which is a continuation-in-part of Ser. No. US 1988-209009, filed on 20 Jun 1988, now patented, Pat. No. US 5149781 which
is a continuation-in-part of Ser. No. US 1987-134130, filed on 17 Dec 1987 And Ser. No. US 1987-133687, filed
on 16 Dec 1987, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Hill, Jr., Robert J.
ASSISTANT EXAMINER: Scheiner, Laurie
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow, Garrett & Dunner
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 29 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 1892
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A previously isolated hepatitis B virus (HBV) integration in a 147 bp cellular DNA fragment linked to hepatocellular carcinoma (HCC) was used as a probe to clone the corresponding complementary DNA from a human liver cDNA **library**. Nucleotide sequence analysis revealed that the overall structure of the cellular gene, which has been named hap, is similar to that of the DNA-binding hormone **receptors**. Six out of seven hepatoma and hepatoma-derived cell-lines express a 2.5 kb hap mRNA species which is undetectable in normal adult and fetal livers, but present in all non-hepatic tissues analyzed. Low stringency hybridization experiments revealed the existence of hap related genes in the human genome. The cloned DNA sequence is useful in the preparation of pure hap **protein** and as a probe in the detection and isolation of complementary DNA and RNA sequences. The hap **protein** is a retinoic acid (RA) **receptor** identified as RAR-.beta.. The RAR-.beta. gene is transcriptionally up-**regulated** by retinoic acid (RA) and its promoter region may contain a RARE (retinoic acid responsive element).

L11 ANSWER 11 OF 26 USPATFULL
ACCESSION NUMBER: 94:42260 USPATFULL
TITLE: Hormone **receptor** compositions and **methods**
INVENTOR(S): Evans, Ronald M., San Diego, CA, United States
Weinberger, Cary A., Silver Spring, MD, United States
Hollenberg, Stanley M., San Diego, CA, United States
Giguere, Vincent, San Diego, CA, United States
Arriza, Jeffrey, Carlsbad, CA, United States
Thompson, Catherine C., La Jolla, CA, United States
Ong, Estelita S., San Diego, CA, United States
PATENT ASSIGNEE(S): The Salk Institute for Biological Studies, La Jolla, CA, United States (U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 5312732	19940517	<--
APPLICATION INFO.:	US 1991-667602	19910307 (7)	

RELATED APPLN. INFO.: Division of Ser. No. US 1987-108471, filed on 20 Oct

1987, now patented, Pat. No. US 5071773 which is a continuation-in-part of Ser. No. US 1986-922585, filed on 24 Oct 1986, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Hill, Jr., Robert J.
ASSISTANT EXAMINER: Ulm, John D.
LEGAL REPRESENTATIVE: Pretty, Schroeder, Brueggemann & Clark
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 95 Drawing Figure(s); 79 Drawing Page(s)
LINE COUNT: 4895
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides substantially pure DNA's comprised of sequences which encode **proteins** having the hormone-binding and/or transcription-activating characteristics of a glucocorticoid **receptor**, a mineralocorticoid **receptor**, or a thyroid hormone **receptor**. The invention also provides various plasmids containing **receptor** sequences which exemplify the DNA's of the invention. The invention further provides **receptor proteins**, including modified functional forms thereof, expressed from the DNA's (or mRNA's) of the invention. In addition to the novel **receptor** DNA, RNA and **protein** compositions, the present invention involves a bioassay for determining the functionality of a **receptor protein**. By using our bioassay system we have discovered that a necessary and sufficient condition for activation of transcription of a gene (G), whose transcription is activated by hormones complexed with **receptors**, is the presence of the hormone and its **receptor** in the cell (C) where (G) is located. As a result of that discovery we have also invented new **methods** for producing desired **proteins** in genetically engineered cells. Two of these **methods** are **methods** of the present invention. The first is a **method** for inducing transcription of a gene whose transcription is activated by hormones complexed with the **receptors**. The second is a **method** for engineering a cell and increasing and controlling production of a **protein** encoded by a gene whose transcription is activated by hormones complexed with **receptor proteins**.

L11 ANSWER 12 OF 26 USPATFULL
ACCESSION NUMBER: 94:26457 USPATFULL
TITLE: Bioassay for identifying ligands for steroid hormone **receptors**
INVENTOR(S): Evans, Ronald M., La Jolla, CA, United States
Hollenberg, Stanley M., Seattle, WA, United States
Giguere, Vincent, Etobicoke, Canada
PATENT ASSIGNEE(S): The Salk Institute for Biological Studies, La Jolla, CA, United States (U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 5298429	19940329	<--
APPLICATION INFO.:	US 1991-807135	19911210 (7)	

RELATED APPLN. INFO.: Division of Ser. No. US 1987-108471, filed on 20 Oct 1987, now patented, Pat. No. US 5071773 which is a continuation-in-part of Ser. No. US 1986-922585, filed on 24 Oct 1986, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Hill, Jr., Robert J.
ASSISTANT EXAMINER: Ulm, John D.
LEGAL REPRESENTATIVE: Pretty, Schroeder, Brueggemann & Clark
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 91 Drawing Figure(s); 79 Drawing Page(s)
LINE COUNT: 4880
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Bioassays are disclosed which are useful for determining whether a

compound is a hormone **receptor** agonist (i.e., is capable of promoting the transcription-activation activities of such **receptors**) or a hormone **receptor** antagonist (i.e., is capable of blocking the transcription-activation activities of such **receptors**). The invention bioassay is conducted by culturing test cells in the presence of at least one compound whose ability to function as a ligand for said **receptor protein** (or functional engineered or modified forms thereof) is sought to be determined. Alternatively, test cells are cultured in medium containing increasing concentrations of at least one compound whose ability to inhibit the transcription activation activity of hormone **receptor** agonists is sought to be determined, and a fixed concentration of at least one agonist for the **receptor protein**. Test cells employed in the practice of the present invention contain non-endogenous DNA which expresses hormone **receptor** (or functional modified forms thereof) and a DNA sequence encoding a hormone response element operatively linked to a reporter gene. The cultured cells are monitored for evidence of transcription of the reporter gene as a function of the concentration of test compound in the culture medium. The variation in transcription levels of the reporter gene as a function of concentration of test compound indicates the ability of test compound to promote or inhibit activation of transcription.

L11 ANSWER 13 OF 26 USPATFULL

ACCESSION NUMBER:	91:100288 USPATFULL
TITLE:	Hormone **receptor**-related bioassays
INVENTOR(S):	Evans, Ronald M., La Jolla, CA, United States Weinberger, Cary A., San Diego, CA, United States Hollenberg, Stanley M., Seattle, WA, United States Giguere, Vincent, Etobicoke, Canada Arriza, Jeffrey, Durham, NC, United States Thompson, Catherine C., Malverne, NY, United States Ong, Estelita S., San Diego, CA, United States
PATENT ASSIGNEE(S):	The Salk Institute for Biological Studies, San Diego, CA, United States (U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 5071773	19911210	<--
APPLICATION INFO.:	US 1987-108471	19871020 (7)	
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1986-922585, filed on 24 Oct 1986, now abandoned		
DOCUMENT TYPE:	Utility		
PRIMARY EXAMINER:	Schwartz, Richard A.		
ASSISTANT EXAMINER:	Ulm, John D.		
LEGAL REPRESENTATIVE:	McCubbrey, Bartels, Meyer & Ward		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	91 Drawing Figure(s); 66 Drawing Page(s)		
LINE COUNT:	4809		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention discloses two hormone **receptor**-related bioassays. The first bioassay is useful for determining whether a **protein** suspected of being a hormone **receptor** has transcription-activating properties of a hormone **receptor**. The second bioassay is useful for evaluating whether compounds are functional ligands for **receptor proteins**. According to the first bioassay, cells that contain non-endogenous DNA which expresses a **protein** suspected of being a hormone **receptor** and which contain a DNA sequence encoding an operative hormone responsive promoter/enhancer element linked to an operative reporter gene, are cultured, the culturing being conducted in a culture medium containing a known hormone, or an analog thereof. The cultured cells are then monitored for induction of the product of the reporter

gene as an indication of functional transcription-activating binding between the hormone or hormone analog and the **protein** suspected of being a hormone **receptor**. According to the second bioassay, cells that contain non-endogenous DNA which expresses hormone **receptor** or a functional engineered or modified form thereof, and which also contain a DNA sequence encoding an operative hormone responsive promoter/enhancer element linked to an operative reporter gene, are cultured, the culturing being conducted in culture medium containing at least one compound whose ability to functionally bind the **receptor protein** is sought to be determined. The cultured cells are then monitored for induction of the product of the report gene as an indicator of functional binding between the compound and the **receptor**.

L11 ANSWER 14 OF 26 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1998045427 PCTFULL
TITLE (ENGLISH): INSULIN-LIKE GROWTH FACTOR AGONIST MOLECULES
TITLE (FRENCH): MOLECULES AGONISTES DU FACTEUR DE CROISSANCE DE L'INSULINOIDE
INVENTOR(S): CLARK, Ross, G.; LOWMAN, Henry, B.; ROBINSON, Iain, C., A., F.
PATENT ASSIGNEE(S): GENENTECH, INC.
LANGUAGE OF PUBL.: English
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9845427	**A2**	**19981015**

DESIGNATED STATES: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
APPLICATION INFO.: WO 1998-US6514 19980331
PRIORITY (ORIGINAL): US 1997-08/825852 19970404
ABEN Compounds are provided that inhibit the interaction of an IGF with any (one) of its binding **proteins** but do not bind to a human IGF **receptor**. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
ABFR L'invention porte sur des composes inhibant l'interaction du facteur de croissance de l'insuline (IGF) avec toutes ses **proteines** de fixation, mais ne se fixant pas au **recepteur** humain de l'IGF. Ces composes agonistes de l'IGF, qui incluent des peptides, s'averent utiles pour accroitre les niveaux d'IGF dans le serum et les tissus des mammiferes.

L11 ANSWER 15 OF 26 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1998021239 PCTFULL
TITLE (ENGLISH): THERAPEUTIC COMPOSITIONS AND **METHODS** AND DIAGNOSTIC ASSAYS FOR TYPE II DIABETES INVOLVING HNF-1
TITLE (FRENCH): COMPOSITIONS ET PROCEDES THERAPEUTHIQUES ET DOSAGES DIAGNOSTIQUES PERMETTANT DE TRAITER DES DIABETES DE TYPE II IMPLIQUANT HNF-1
INVENTOR(S): GLUCKSMANN, Alexandra, M.
PATENT ASSIGNEE(S): MILLENNIUM PHARMACEUTICALS, INC.
LANGUAGE OF PUBL.: English
LANGUAGE OF FILING: English

DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9821239	**A2**	**19980522**
DESIGNATED STATES:	AU CA JP AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE		
APPLICATION INFO.:	WO 1997-US20532		19971107
PRIORITY (ORIGINAL):	US 1996-08/748229		19961112
	US 1996-08/749431		19961115
	US 1996-08/760246		19961204
	US 1997-08/782047		19970110

ABEN **Methods** and compositions for treating type II diabetes; and type
II diabetes diagnostics are disclosed.
ABFR La presente invention concerne des procedes et des compositions permettant de traiter des diabetes de type II. La presente invention concerne, egalement, des diagnostics de diabetes de type II.

L11 ANSWER 16 OF 26 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1998019162 PCTFULL
TITLE (ENGLISH): IDENTIFICATION OF DRUGS USING COMPLEMENTARY COMBINATORIAL **LIBRARIES**
TITLE (FRENCH): IDENTIFICATION DE MEDICAMENTS AU MOYEN DE BIBLIOTHEQUES COMBINATOIRES COMPLEMENTAIRES
INVENTOR(S): FOWLKES, Dana, M.; KAY, Brian, K.; FRELINGER, Jeffrey, A.; HYDE#ndash#DERUYSCHER, Robin, Parish
PATENT ASSIGNEE(S): NOVALON PHARMACEUTICAL CORPORATION
LANGUAGE OF PUBL.: English
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9819162	**A1**	**19980507**
DESIGNATED STATES:	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1997-US19638		19971031
PRIORITY (ORIGINAL):	US 1996-08/740671		19961031

ABEN The present invention is directed to the identification of compounds in a compound **library** which can mediate the biological activity of a target **receptor protein**, even when the ligands which mediate that activity through binding to that **receptor** are not already known. The **method** comprises three steps: (1) Screen at least one potential surrogate combinatorial **library** for members (preferably peptides or **nucleic acids**) binding to the target **protein** (TP) and hence capable of use as surrogates for the unknown ligand in steps (2) and (3).

(2) Screen at least one complementary **library**, preferably a combinatorial **library** (which is not limited to, and may not even include, peptides, or **nucleic acids** and hence is referred to

on occasion as a
"compound **library**"), for compounds which inhibit the binding of one or
more surrogates from step (1) to TP, and, optionally, (3) determine whether the inhibitory compound mediates the biological activity of the said TP.

ABFR L'invention concerne l'identification de composes dans un bibliotheque de composes, qui peuvent etre a l'origine de l'activite biologique d'une **proteine receptrice** cible meme lorsque les ligands a
l'origine de l'activite par liaison a ce **recepteur** ne sont pas encore
connus. Le procede consiste: (1) a cribler au moins une bibliotheque combinatoire de substituts potentiels pour des elements (de preference des peptides ou des acides nucleiques) se liant a la **proteine** cible (PT)
et donc pouvant etre utilises pour le ligand inconnu des etapes (2) et (3); (2) a cribler au moins une bibliotheque complementaire, de preference une bibliotheque combinatoire, (qui peut comporter, entre autres, des peptides ou des acides nucleiques et donc appelee parfois "bibliotheque de composes") pour des composes qui inhibent la liaison d'un ou plusieurs substituts de l'etape (1) de PT, et eventuellement (3) a determiner si le compose inhibiteur est a l'origine ou non de l'activite biologique de ladite PT.

L11 ANSWER 17 OF 26 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1998014593 PCTFULL
TITLE (ENGLISH): HUMAN TELOMERASE CATALYTIC SUBUNIT
TITLE (FRENCH): SOUS#ndash#UNITE CATALYTIQUE DE LA TELOMERASE D'ORIGINE HUMAINE
INVENTOR(S): CECH, Thomas, R.; LINGNER, Joachim; NAKAMURA, Toru; CHAPMAN, Karen, B.; MORIN, Gregg, B.; HARLEY, Calvin, B.; ANDREWS, William, H.
PATENT ASSIGNEE(S): GERON CORPORATION; UNIVERSITY TECHNOLOGY CORPORATION
LANGUAGE OF PUBL.: English
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9814593	**A2**	**19980409**
DESIGNATED STATES:	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1997-US17885		19971001
PRIORITY (ORIGINAL):	US 1996-08/724643		19961001
	US 1997-08/844419		19970418
	US 1997-08/846017		19970425
	US 1997-08/851843		19970506
	US 1997-08/854050		19970509
	US 1997-08/911312		19970814
	US 1997-08/912951		19970814
	US 1997-08/915503		19970814

ABEN The invention provides compositions and **methods** related to human
telomerase reverse transcriptase (hTRT), the catalytic **protein** subunit
of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms,
and for identification and screening of compounds and treatments useful

for treatment of diseases such as cancers.

ABFR La presente invention se rapporte a des compositions et a des procedes relatifs a la transcriptase inverse de la telomerase humaine (hTRT human telomerase reverse transcriptase), la sous#ndash# unite proteique catalytique de la telomerase d'origine humaine. Les polynucleotides et les polypeptides de la presente invention s'averent utiles s'agissant du diagnostic, du pronostic et du traitement de certaines maladies humaines, ils servent a modifier la capacite de proliferation de cellules et d'organismes, et a identifier et a analyser des composes et des traitements adaptes a des maladies telles que les cancers.

L11 ANSWER 18 OF 26 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1998013513 PCTFULL
TITLE (ENGLISH): **METHODS** AND COMPOSITIONS FOR IDENTIFYING **RECEPTOR** EFFECTORS
TITLE (FRENCH): PROCEDES ET COMPOSITIONS POUR IDENTIFIER DES MODULATEURS DE **RECEPTEUR**
INVENTOR(S): TRUEHEART, Joshua; PAUL, Jeremy, I.; FUERNKRANZ, Hans,
A.; NATHAN, Debra; HOLMES, Scott
PATENT ASSIGNEE(S): CADUS PHARMACEUTICAL CORPORATION
LANGUAGE OF PUBL.: English
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9813513	**A2**	**19980402**

DESIGNATED STATES: AL AM AT AU AZ BA BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

APPLICATION INFO.:	WO 1997-US17159	19970924
PRIORITY (ORIGINAL):	US 1996-08/718910	19960924
	US 1997-08/851469	19970505

ABEN The present invention makes available a rapid, effective assay for screening and identifying pharmaceutically effective compounds that specifically interact with and modulate the activity of a cellular **protein**, e.g., a **receptor** or ion channel. The subject assay enables rapid screening of large numbers of compounds to identify those which act as an agonist or antagonist to the bioactivity of the cellular **protein**. The subject assay is particularly amenable for identifying surrogate ligands for **receptors** especially from small molecule or peptide **libraries** or from peptides produced by an autocrine system.

ABFR L'invention concerne un essai rapide et efficace pour le criblage et l'identification de composes pharmaceutiquement efficaces ayant une interaction specifique avec l'activite d'une **proteine** cellulaire et modulant cette activite (par exemple, **recepteur** ou canal ionique). L'essai en question permet de cribler rapidement un grand nombre de composes, pour identifier parmi eux les agonistes ou les antagonistes de la bioactivite d'une **proteine** cellulaire. Ce type d'essai est particulierement approprie a l'identification de substituts de ligands pour **recepteurs**, en particulier parmi les banques de molecules ou de peptides de petite taille ou parmi les peptides emanant d'un systeme autocrine.

L11 ANSWER 19 OF 26 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1998011254 PCTFULL
TITLE (ENGLISH): MUTATIONS IN THE DIABETES SUSCEPTIBILITY GENES HEPATOCYTE **NUCLEAR** FACTOR (HNF) 1 ALPHA (#agr#), HNF-1#bgr# AND HNF-4#agr#
TITLE (FRENCH): MUTATIONS DANS LES GENES DE SUSCEPTIBILITE AU DIABETE FACTEUR NUCLEAIRE D'HEPATOCYTE (HNF) 1 ALPHA (#agr#), HNF-1#bgr# ET HNF-4#agr#
INVENTOR(S): BELL, Graeme, I.; YAMAGATA, Kazuya; ODA, Naohisa; KAISAKI, Pamela, J.; FURUTA, Hiroto; MENZEL, Stephan; HORIKAWA, Yukio
PATENT ASSIGNEE(S): ARCH DEVELOPMENT CORPORATION
LANGUAGE OF PUBL.: English
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9811254	**A1**	**19980319**

DESIGNATED STATES: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

APPLICATION INFO.:	WO 1997-US16037	19970910
PRIORITY (ORIGINAL):	US 1996-60/025719	19960910
	US 1996-60/028056	19961002
	US 1996-60/029679	19961030

ABEN The present invention relates generally to the fields diabetes. More particularly, it concerns the identification of genes responsible for NIDDM for use in diagnostics and therapeutics. The present invention demonstrates that the MODY3 locus is, in fact, the HNF-1#agr# gene, MODY4 locus is the HN-F1#bgr# and the MODY1 locus is the HNF-4#agr# gene.

The invention further relates to the discovery that analysis of mutations in the HNF-1#agr#, HNF-1#bgr# and HNF-4#agr# genes can be diagnostic for diabetes. The invention also contemplates **methods** of
treating diabetes in view of the fact that HNF-1#agr#, HNF-1#bgr# and HNF-4#agr# mutations can cause diabetes.

ABFR La presente invention se rapporte de maniere generale au domaine du diabete et concerne plus particulierement l'identification des genes responsables du diabete non insulino-dependant, destinee a des fins diagnostiques et therapeutiques. L'invention demontre que le locus du diabete 3 de la maturite chez les jeunes (MODY3) est, en fait, le gene HNF-1#agr#, celui de MODY4 est le gene HNF-1#bgr# et celui de MODY1 est le gene HNF-4#agr#. En outre, l'invention se rapporte a la decouverte selon laquelle l'analyse des mutations dans les genes HNF-1#agr#, HNF-1#bgr# et HNF-4#agr# peut permettre de diagnostiquer le diabete. L'invention envisage egalement des **methodes** de traitement du diabete sur
la base du fait que les mutations des genes HNF-1#agr#, HNF-1#bgr# et HNF-4#agr# peuvent causer le diabete.

L11 ANSWER 20 OF 26 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1998001460 PCTFULL
TITLE (ENGLISH): BRCA1 COMPOSITIONS AND **METHODS** FOR THE DIAGNOSIS AND TREATMENT OF BREAST CANCER
TITLE (FRENCH): COMPOSITIONS BRCA1 ET PROCEDES DE DIAGNOSTIC ET DE TRAITEMENT DU

CANCER DU SEIN

INVENTOR(S): LEE, Wen-Hwa; CHEN, Yumay; CHEN, Chi-Fen; CHEN, Phang-Lang; FARMER, Andrew, A.; JONES, Diane, C.; ALLRED, D., Craig; OSBORNE, C., Kent

PATENT ASSIGNEE(S): THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

LANGUAGE OF PUBL.: English

LANGUAGE OF FILING: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9801460	**A1**	**19980115**

DESIGNATED STATES: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

APPLICATION INFO.: WO 1997-US11946 19970708

PRIORITY (ORIGINAL): US 1996-60/015863 19960708

ABEN Disclosed are **methods** and compositions relating to the diagnosis and treatment of breast and related cancers. Compositions and **methods** for the detection of the BRCA1 gene product in vivo and in vitro are disclosed, as well as **methods** for diagnosing aberrant localization of BRCA1 **protein** in cells using anti-BRCA1 antibodies. Also disclosed are **methods** for identifying BRCA1-associated **proteins** which function in the proper translocation of the BRCA1 gene product to the cell nucleus.

ABFR L'invention concerne des procedes et des compositions s'appliquant au diagnostic et au traitement du cancer du sein et autres cancers apparentes. L'invention concerne egalement des compositions et des procedes de detection du produit genique BRCA1 in vivo et in vitro , ainsi que des procedes de diagnostic de localisation aberrante de la **proteine** BRCA1 dans des cellules mettant en oeuvre des anticorps anti-BRCA1. L'invention concerne de plus des procedes d'identification des **proteines** associees a BRCA1 qui agissent dans la translocation correcte du produit genique BRCA1 vers le noyau cellulaire.

L11 ANSWER 21 OF 26 PCTFULL COPYRIGHT 2001 MicroPatent

ACCESSION NUMBER: 1995013373 PCTFULL

TITLE (ENGLISH): UBIQUITOUS **NUCLEAR RECEPTOR**: COMPOSITIONS AND **METHODS**

TITLE (FRENCH): **RECEPTEUR** NUCLEAIRE UBIQUISTE: COMPOSITIONS ET PROCEDES

INVENTOR(S): LIAO, Shutsung; SONG, Ching

PATENT ASSIGNEE(S): ARCH DEVELOPMENT CORPORATION; LIAO, Shutsung; SONG, Ching

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9513373	**A1**	**19950518**

DESIGNATED STATES: AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN KE SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

MR NE SN TD TG
APPLICATION INFO.: WO 1994-US12883 19941108
PRIORITY (ORIGINAL): US 1993-8/152003 19931110
ABEN The invention relates generally to compositions of and **methods** for obtaining ubiquitous, **nuclear receptor** (UR) polypeptides. The invention also relates to polynucleotides encoding UR polypeptides, recombinant host cells and vectors containing UR-encoding polynucleotide sequences, and recombinant UR polypeptides. By way of example, the invention discloses the cloning and functional expression of at least two different UR polypeptides. The invention also includes **methods** for using the isolated, recombinant **receptor** polypeptides in assays designed to select substances which interact with UR polypeptides for use in diagnostic, drug design and therapeutic applications.
ABF Cette invention concerne globalement des compositions et des procedes d'obtention de polypeptides de **recepteurs** nucleaires ubiquistes (UR), ainsi que des polynucleotides codant lesdits polypeptides UR, des cellules hotes et des vecteurs de recombinaison contenant des sequences polynucleotidiques codant UR, et des polypeptides UR de recombinaison. Cette invention presente, par exemple, le clonage et l'expression fonctionnelle d'au moins deux polypeptides UR differents; ainsi que des procedes d'utilisation des polypeptides de **recepteurs** de recombinaison isoles dans des analyses effectuees pour selectionner des substances qui interagissent avec les polypeptides UR qu'on utilise dans des applications de diagnostic, de preparation de medicaments et de therapie.

L11 ANSWER 22 OF 26 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1993015216 PCTFULL
TITLE (ENGLISH): NOVEL HETERODIMERIC **NUCLEAR RECEPTORS PROTEINS**, GENES ENCODING SAME, AND USAGE THEREOF
TITLE (FRENCH): NOUVELLES **PROTEINES** POUR **RECEPTEURS** NUCLEAIRES HETERODIMERES, GENES LES CODANTS ET LEUR UTILISATION
INVENTOR(S): LEID, Mark; KASTNER, Philippe; CHAMBON, Pierre
PATENT ASSIGNEE(S): INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE LOUIS PASTEUR, STRASBOURG I; E.R. SQUIBB & SONS, INC.; LEID, Mark; KASTNER, Philippe; CHAMBON, Pierre
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9315216	**A1**	**19930805**

DESIGNATED STATES: CA JP US AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
APPLICATION INFO.: WO 1993-US639 19930125
PRIORITY (ORIGINAL): US 1992-7/825667 19920124
ABEN The present invention is based in part on the novel observation that two different types of **nuclear receptors**, retinoic acid **receptors** (RAR) and thyroid **receptors** (TR) dimerize with an RX **receptor** (RXR) to form a heterodimer which is capable of binding to retinoic acid response elements (RARE) or thyroid **receptor** response elements (TRE) at physiological conditions. Based on this observation, the present invention provides novel heterodimeric **proteins**, **methods** of identifying agents capable of binding the heterodimers of the present invention,

methods of identifying DNA sequences capable of being bound by the
heterodimers and **methods** to identify RA metabolic enzymes and **proteins**
which are required for the activation function of **nuclear receptors**.

ABF La presente invention est basee en partie sur la nouvelle observation que deux types differents de **recepteurs** nucleaires, les **recepteurs** d'acide retinoique (RAR) et les **recepteurs** thyroides (RT) se dimerisent avec un **recepteur** RX (RRX) pour former un heterodimere pouvant se lier a des elements de reponse d'acide retinoique (ERAR) ou a des elements de reponse de **recepteurs** thyroides (ERT) dans des conditions physiologiques. A partir de cette observation, la presente invention presente de nouvelles **proteines** heterodimeres, des procedes d'identification d'agents pouvant lier les heterodimeres de l'invention, des procedes d'identification de sequences d'ADN pouvant etre liees par les heterodimeres et des procedes d'identification des enzymes et de **proteines** metaboliques RA necessaires a la fonction d'activation de **recepteurs** nucleaires.

L11 ANSWER 23 OF 26 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1992011365 PCTFULL
TITLE (ENGLISH): LIVER ENRICHED TRANSCRIPTION FACTOR
TITLE (FRENCH): FACTEUR DE TRANSCRIPTION ENRICHI PAR EXTRAITS HEPATIQUES
INVENTOR(S): SLADEK, Frances, M.; ZHONG, Weimin; DARNELL, James, E., Jr.
PATENT ASSIGNEE(S): THE ROCKEFELLER UNIVERSITY; SLADEK, Frances, M.; ZHONG, Weimin; DARNELL, James, E., Jr.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9211365	**A1**	**19920709**

DESIGNATED STATES: AT AU BE CA CH DE DK ES FR GB GR IT JP LU MC NL SE US
APPLICATION INFO.: WO 1991-US9733 19911223
PRIORITY (ORIGINAL): US 1990-631720 19901221

ABEN HNF-4 (hepatocyte **nuclear** factor 4) is a **protein** enriched in liver extracts that binds to sites required for the transcription of the transthyretin (TTR) and apolipoprotein CIII (apoCIII) genes (Costa et al., 1989; Costa et al., 1990; Leff et al., 1989). We have purified HNF-4 **protein** (54 kD) and isolated a cDNA clone encoding the **protein**. HNF-4 is a member of the steroid hormone **receptor** superfamily with an unusal amino acid in the conserved "knuckle" of the first zinc finger (DGCKG). This and the fact that HNF-4 does not bind significantly to estrogen, thyroid hormone or glucocorticoid response elements indicate that HNF-4 may represent a new subfamily. HNF-4 binds to its recognition site as a dimer and activates transcription in a sequence-specific fashion in nonhepatic (HeLa) cells. HNF-4 mRNA is present in kidney and intestine as well as liver but is absent in other tissues. DNA binding data suggest that HNF-4 could be identical to liver factor A1 (LF-A1), a factor previously shown to **regulate** the transcription of the alpha-1 antitrypsin, apolipoprotein A1 and pyruvate kinase genes.

ABF HNF-4 (facteur nucleaire hepatocyte 4) est une **proteine** enrichie

par des extraits de foie, qui s'agglutine a des sites necessaires a la transcription des genes de la transthyretine (TTR) et de l'apolipoproteine CIII (apoCIII) (Costa et al., 1989; Costa et al., 1990; Leff et al., 1989). Nous avons purifie la **proteine** HNF-4 (54kD) et isole un clone d'ADNc codant la **proteine**. HNF-4 est un membre de la superfamille du **recepteur** de l'hormone steroide, possedant un acide amine inhabituel dans l'"articulation" conservee du premier doigt de zinc (DGCKG). Ceci et le fait que HNF-4 ne s'agglultine pas de facon substantielle sur l'oestrogene, l'hormone thyroidienne ou des elements de reaction aux glucocorticoides, indique que HNF-4 represente eventuellement une nouvelle sous-famille. HNF-4 s'agglutine sur son site de reconnaissance en tant que dimetre et active la transcription de facon specifico-sequentielle dans les cellules non-hepatiques (HeLa). HNF-4 mRNA est presente dans les reins et l'intestin comme dans le foie, mais absente dans d'autres tissus. Les donnees de liaison de l'ADN suggerent que HNF-4 pourrait etre identique au facteur hepatique A1 (LF-A1), lequel s'est avere precedemment reguler la transcription des genes de alpha-1 antitrypsine, apolipoproteine A1 et pyruvate kinase.

L11 ANSWER 24 OF 26 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1989005854 PCTFULL
TITLE (ENGLISH): A NOVEL STEROID/THYROID HORMONE **RECEPTOR** -RELATED GENE, WHICH IS INAPPROPRIATELY EXPRESSED IN HUMAN HEPTOCELLULAR CARCINOMA, AND WHICH IS A RETINOIC ACID **RECEPTOR**
TITLE (FRENCH): NOUVEAU GENE ASSOCIE AU **RECEPTEUR** D'HORMONES STEROIDIQUES/THYROIDIENNES, QUI EST EXPRIME DE FACON INAPPROPRIEE DANS LE CARCINOME HEPATOCELLULAIRE DE L'HOMME ET QUI CONSTITUE UN **RECEPTEUR** D'ACIDE RETINOIQUE
INVENTOR(S): BLAUDIN DE THE, Hugues; MARCHIO, Agnes; TIOLLAIS, Pierre; DEJEAN, Anne
PATENT ASSIGNEE(S): INSTITUT PASTEUR
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 8905854	**A1**	**19890629**
DESIGNATED STATES: JP		
APPLICATION INFO.: WO 1988-EP1180		19881216
PRIORITY (ORIGINAL): US 1987-133687		19871216
US 1987-134130		19871217
US 1988-209009		19880620
US 1988-278136		19881130

ABEN A previously isolated hepatitis B virus (HBV) integration in a 147 bp cellular DNA fragment linked to hepatocellular carcinoma (HCC) was used as a probe to clone the corresponding complementary DNA from a human liver cDNA **library**. Nucleotide sequence analysis revealed that the overall structure of the cellular gene, which has been named hap, is similar to that of the DNA-binding hormone **receptors**. Six out of seven hepatoma and hepatoma-derived cell-lines express a 2.5 kb hap mRNA species which is undetectable in normal adult and fetal livers, but present in all non-hepatic tissues analyzed. Low stringency hybridization experiments revealed the existence of hap related genes in the human genome. The cloned DNA sequence is useful in the preparation of pure hap **protein** and as a probe in the detection and isolation of

complementary DNA and RNA sequences. The hap **protein** is a retinoic acid
(RA) **receptor** identified as RAR-beta.

ABF Une integration du virus de l'hepatite B (HBV) prealablement isole dans un fragment d'ADN cellulaire de 147 bp relie au carcinome hepatocellulaire (HCC) a ete utilisee comme sonde pour cloner l'ADN complementaire correspondant a partir d'une bibliotheque d'ADNc du foie humain. L'analyse de la sequence de nucleotides a revele que la structure globale du gene cellulaire, appelee hap, est similaire a celle des **recepteurs** d'hormones de liaison d'ADN. Six lignees cellulaires de
l'hepatome et derivees de l'hepatome sur sept expriment une espece d'ARNm d'hap de 2,5 kb, qui n'est pas detectable dans le foie d'adultes normaux et de foetus, mais qui est presente dans tous les tissus non hepatiques analyses. Des experiences d'hybridation avec un resserrement faible ont revele l'existence de genes associes a hap dans le genome humain. La sequence d'ADN clonee est utile dans la preparation de **proteine** d'hap pur et comme sonde pour detecter et isoler des sequences
d'ADN et d'ARN complementaires. La **proteine** d'hap constitue un **recepteur**
d'acide retinoique (RA) dit RAR-beta.

L11 ANSWER 25 OF 26 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1988003168 PCTFULL
TITLE (ENGLISH): HORMONE **RECEPTOR** COMPOSITIONS AND **METHODS**
TITLE (FRENCH): COMPOSITIONS **RECEPTRICES** D'HORMONES ET PROCEDES
INVENTOR(S): EVANS, Ronald, Mark; WEINBERGER, Cary, A.; HOLLENBERG,
Stanley, Mark; GIGUERE, Vincent; ARRIZA, Jeffrey, Louis; THOMPSON, Catherine, Caroline; ONG, Estelita, Sebastian
PATENT ASSIGNEE(S): THE SALK INSTITUTE FOR BIOLOGICAL STUDIES
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 8803168	**A1**	**19880505**

DESIGNATED STATES: AT AU BE CH DE FR GB IT JP LU NL SE
APPLICATION INFO.: WO 1987-US2782 19871023
PRIORITY (ORIGINAL): US 1986-922585 19861024
US 1987-108471 19871020

ABEN Substantially pure DNA and plasmids containing the DNA which is comprised of sequences which encode **proteins** having hormone-binding
and/or transcription-activating characteristics of a glucocorticoid **receptor**, a mineralocorticoid **receptor**, or a thyroid hormone **receptor**.
The invention further provides **receptor proteins** and modified functional
forms thereof. The invention also provides a bioassay for determining the functionality of a **receptor protein** and new **methods** for producing
desired **proteins** in genetically engineered cells. One **method** involves
inducing transcription of a gene whose transcription is activated by hormones complexed with **receptors**; the second is a **method** for
engineering a cell and increasing and controlling production of a **protein** encoded by a gene whose transcription is activated by hormones
complexed with **receptor proteins**. ADN essentiellement pur et plasmides

contenant l'ADN comprenant des sequences de codage de **proteines** presentant les caracteristiques de liaison d'hormones et/ou d'activation de la transcription d'un **recepteur** de glucocorticoides, d'un **recepteur** de mineralocorticoides ou d'un **recepteur** de l'hormone thyroidienne. Sont egalement decrites des **proteines receptrices** et des formes fonctionnelles modifiees de ces **proteines**. L'invention permet aussi d'effectuer une analyse biologique pour determiner la fonctionnalite d'une **proteine receptrice**, et decrit de nouveaux procedes de production des **proteines** desirees dans des cellules modifiees grace a des techniques du genie genetique. Un procede consiste a induire la transcription d'un gene dont la transcription est activee par des hormones complexees avec des **recepteurs**; un deuxieme procede permet de modifier une cellule et d'accroitre et de reguler la production d'une **proteine** codee par un gene dont la transcription est activee par des hormones complexees avec des **proteines receptrices**.

L11 ANSWER 26 OF 26 EUROPATFULL COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 733705 EUROPATFULL EW 199639 FS OS
TITLE: Hormone **receptor** compositions and **methods**.
Hormon-Rezeptorverbindungen und **Methoden**.
Compositions **receptrices** d'hormones et procedes.
INVENTOR(S): Evans, Ronald M., 3702 Clark Street, San Diego, Clifornia 92100, US;
Weinberger, Gary A., 12620 Dalewood Drive, Silver Spring, Maryland 20906, US;
Hollenberg, Stanley Mark, 6413 SW Roundtree Court, Portland, Oregon 97219, US;
Giguere, Vincent, 3425 Lebon Drive, No. 731, San Diego, California 92122, US;
Arriza, Jeffrey Louis, 331 Redwood, Carlsbad, California 92008, US;
Thompson, Catherine Caroline, 3903 Miramar Street, LaJolla, California 92037, US;
Ong, Estelita Sebastian, 6307 Hannon Court, San Diego, California 92117, US
PATENT ASSIGNEE(S): THE SALK INSTITUTE FOR BIOLOGICAL STUDIES, 10010 North Torrey Pines Road, La Jolla California 92037, US
PATENT ASSIGNEE NO: 273851
AGENT: Kolb, Helga, Dr. Dipl.-Chem. et al, Hoffmann, Eitle & Partner, Patent-und Rechtsanwaelte, Arabellastrasse 4, 81925 Muenchen, DE
AGENT NUMBER: 49372
OTHER SOURCE: ESP1996051 EP 0733705 A1 960925
SOURCE: Wila-EPZ-1996-H39-T1a
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R FR; R GB; R IT; R LI; R LU; R NL; R SE
PATENT INFO.PUB.TYPE: EPA1 EUROPAEISCHE PATENTANMELDUNG
PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 733705	**A1**	**19960925**

'OFFENLEGUNGS' DATE: 19960925
APPLICATION INFO.: EP 1995-120305 19871023
PRIORITY APPLN. INFO.: US 1986-922585 19861024
US 1987-108471 19871020
RELATED DOC. INFO.: EP 287653 DIV
ABEN Substantially pure DNA and plasmids containing the DNA which is comprised of sequences which encode **proteins** having hormone-binding and/or transcription-activating characteristics of a thyroid hormone. The invention further provides **receptor proteins** and modified functional forms for producing desired **proteins** in genetically engineered cells. One **method** involves inducing transcription of a gene whose transcription is activated by hormones complexed with **receptors**; the second is a **method** for engineering a cell and increasing and controlling production of a **protein** encoded by a gene whose transcription is activated by hormones complexed with **receptor proteins**.